IFM Investors Pty Ltd Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

IFM Investors Pty Ltd boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,285 shares of the biopharmaceutical company's stock after purchasing an additional 1,935 shares during the period. IFM Investors Pty Ltd's holdings in Regeneron Pharmaceuticals were worth $14,768,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in REGN. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after purchasing an additional 686 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in Regeneron Pharmaceuticals by 107.7% during the 4th quarter. Jones Financial Companies Lllp now owns 812 shares of the biopharmaceutical company's stock valued at $578,000 after purchasing an additional 421 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in Regeneron Pharmaceuticals by 26.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,627 shares of the biopharmaceutical company's stock valued at $3,296,000 after purchasing an additional 981 shares during the last quarter. Keybank National Association OH grew its stake in Regeneron Pharmaceuticals by 6.5% in the 4th quarter. Keybank National Association OH now owns 1,239 shares of the biopharmaceutical company's stock worth $883,000 after acquiring an additional 76 shares in the last quarter. Finally, Victory Capital Management Inc. grew its stake in Regeneron Pharmaceuticals by 44.8% in the 4th quarter. Victory Capital Management Inc. now owns 139,891 shares of the biopharmaceutical company's stock worth $99,649,000 after acquiring an additional 43,282 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Argus downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Morgan Stanley dropped their target price on shares of Regeneron Pharmaceuticals from $958.00 to $755.00 and set an "overweight" rating on the stock in a research note on Monday, June 2nd. Guggenheim restated a "buy" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, May 30th. UBS Group dropped their target price on shares of Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. Finally, Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $822.58.

Regeneron Pharmaceuticals Stock Down 1.7%

REGN traded down $9.25 during trading on Monday, hitting $538.11. The stock had a trading volume of 959,668 shares, compared to its average volume of 907,598. The company has a market capitalization of $58.09 billion, a PE ratio of 13.70, a PEG ratio of 2.00 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.03 and a current ratio of 4.93. The stock has a 50 day simple moving average of $547.93 and a two-hundred day simple moving average of $623.60.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. Regeneron Pharmaceuticals's revenue was down 3.7% on a year-over-year basis. During the same quarter last year, the business earned $9.55 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.